Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The primary objectives of this study are:

• To estimate the incidence rate of unexpected adverse events

• To characterize the bleeding events and assess risk factors of bleeding

• To identify ancillary baseline variables that may also be associated with adverse outcomes

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Pfizer
• Treatments: Apixaban

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Patients who are beginning to receive the treatment with this product under the approved indications, dosage, and administration will be included in this study

Exclusion Criteria:

• Patients who are receiving Eliquis outside of its approved indication will be excluded from this study